A Safety and Tolerability Study of Thin Film Freeze-Dried Tacrolimus for Local Pulmonary Drug Delivery in Human Subjects

Due to the low and erratic bioavailability of oral tacrolimus (TAC), the long-term survival rate following lung transplantation remained low compared to other solid organs. TAC was reformulated and developed as inhaled formulations by thin film freezing (TFF). Previous studies reported that inhaled TAC combined with 50% w/w lactose (LAC) was safe and effective for the treatment of lung transplant rejection in rodent models. In this study, we aimed to investigate the safety and tolerability of TFF TAC-LAC in human subjects. The formulation can be delivered to the lung as colloidal dispersions after reconstitution and as a dry powder. Healthy subjects inhaled TAC-LAC colloidal dispersions at 3 mg TAC/dose via a vibrating mesh nebulizer in the first stage of this study and TAC-LAC dry powder at 3 mg TAC/dose via a single dose dry powder inhaler in the second stage. Our results demonstrated that oral inhalation of TAC-LAC colloidal dispersions and dry powder exhibited low systemic absorption. Additionally, they were well-tolerated with no changes in CBC, liver, kidney, and lung functions. Only mild adverse side effects (e.g., cough, throat irritation, distaste) were observed. In summary, pulmonary delivery of TFF TAC-LAC would be a safe and promising therapy for lung transplant recipients.

[1]  K. Khush,et al.  The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 37th adult lung transplantation report - 2020; focus on deceased donor characteristics. , 2020, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[2]  R. Williams,et al.  Development of Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing , 2020, bioRxiv.

[3]  A. Dolocan,et al.  Using thin film freezing to minimize excipients in inhalable tacrolimus dry powder formulations. , 2020, International journal of pharmaceutics.

[4]  H. Smyth,et al.  Post-inhalation cough with therapeutic aerosols: Formulation considerations. , 2020, Advanced drug delivery reviews.

[5]  G. Verleden,et al.  Survival in adult lung transplantation: where are we in 2020? , 2020, Current opinion in organ transplantation.

[6]  D. Dilling,et al.  Immunosuppressive strategies in lung transplantation , 2020, Annals of translational medicine.

[7]  B. Meiser,et al.  The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth adult lung and heart-lung transplant report-2018; Focus theme: Multiorgan Transplantation. , 2018, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[8]  Scott B. Johnson,et al.  The efficacy of inhaled nanoparticle tacrolimus in preventing rejection in an orthotopic rat lung transplant model , 2017, The Journal of thoracic and cardiovascular surgery.

[9]  G. Snell,et al.  Clinical Challenges of Tacrolimus for Maintenance Immunosuppression Post-Lung Transplantation. , 2017, Transplantation proceedings.

[10]  A. Aliverti,et al.  Air Stacking: A Detailed Look Into Physiological Acute Effects on Cough Peak Flow and Chest Wall Volumes of Healthy Subjects , 2017, Respiratory Care.

[11]  G. Angyalosi,et al.  Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study , 2016, Current medical research and opinion.

[12]  P. Jaksch,et al.  Immunosupressive therapy in the lung transplant recipient , 2015 .

[13]  G. Verleden,et al.  An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome , 2014, European Respiratory Journal.

[14]  K. Raza,et al.  Immunosuppression in lung transplantation. , 2014, Journal of Thoracic Disease.

[15]  L. Lund,et al.  The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Adult Lung and Heart-Lung Transplant Report--2013; focus theme: age. , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[16]  Alan B. Watts,et al.  Respirable Low-Density Microparticles Formed In Situ from Aerosolized Brittle Matrices , 2013, Pharmaceutical Research.

[17]  Alan B. Watts,et al.  Preclinical evaluation of tacrolimus colloidal dispersion for inhalation. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[18]  F. Blankenberg,et al.  Mechanisms behind local immunosuppression using inhaled tacrolimus in preclinical models of lung transplantation. , 2010, American journal of respiratory cell and molecular biology.

[19]  E. F. Costa,et al.  Chronic kidney disease after lung transplantation: incidence, risk factors, and treatment. , 2010, Transplantation proceedings.

[20]  Scott B. Johnson,et al.  Characterization and pharmacokinetic analysis of tacrolimus dispersion for nebulization in a lung transplanted rodent model. , 2010, International journal of pharmaceutics.

[21]  Y. Weng,et al.  Tacrolimus versus cyclosporine for adult lung transplant recipients: a meta-analysis. , 2009, Transplantation proceedings.

[22]  K. Johnston,et al.  Nebulization of nanoparticulate amorphous or crystalline tacrolimus--single-dose pharmacokinetics study in mice. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[23]  S. Anderson,et al.  Inhaled mannitol improves lung function in cystic fibrosis. , 2008, Chest.

[24]  P. Reese,et al.  Chronic kidney disease after nonrenal solid-organ transplantation. , 2007, Journal of the American Society of Nephrology : JASN.

[25]  Troy Purvis.  Nanoparticle Formulations of Poorly Water Soluble Drugs and Their Action In Vivo and In Vitro , 2007 .

[26]  G. Patterson,et al.  A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[27]  H. Reichenspurner,et al.  Effect of Inhaled Tacrolimus on Cellular and Humoral Rejection to Prevent Posttransplant Obliterative Airway Disease , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[28]  T. Nagayasu,et al.  Efficacy and safety of inhaled tacrolimus in rat lung transplantation. , 2007, The Journal of thoracic and cardiovascular surgery.

[29]  M. Kamler,et al.  Tacrolimus pharmacokinetics in lung transplantation: new strategies for monitoring. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[30]  H. Reichenspurner,et al.  Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial. , 2003, The Journal of thoracic and cardiovascular surgery.

[31]  L. Shaw,et al.  Clinical Utility of Monitoring Tacrolimus Blood Concentrations in Liver Transplant Patients , 2001, Journal of clinical pharmacology.

[32]  H. Reichenspurner,et al.  Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[33]  R. Bolman,et al.  Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. , 1997, The Journal of thoracic and cardiovascular surgery.

[34]  T. Starzl,et al.  Clinical Pharmacokinetics of Tacrolimus , 1995, Clinical pharmacokinetics.

[35]  B. Griffith,et al.  Clinical trial of tacrolimus versus cyclosporine in lung transplantation. , 1995, The Annals of thoracic surgery.

[36]  T. Starzl,et al.  Strategy of FK 506 therapy in liver transplant patients: effect of graft function. , 1991, Transplantation proceedings.

[37]  Stuart L. Schreiber,et al.  Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes , 1991, Cell.

[38]  T. Starzl,et al.  THE EFFECT OF GRAFT FUNCTION ON FK506 PLASMA LEVELS, DOSAGES, AND RENAL FUNCTION, WITH PARTICULAR REFERENCE TO THE LIVER , 1991, Transplantation.

[39]  L. Lund,et al.  The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Lung and Heart-Lung Transplant Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[40]  M. Konstan,et al.  Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. , 2011, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[41]  K. Johnston,et al.  Use of thin film freezing to enable drug delivery : a review , 2009 .